Mean Arterial Pressure After Out-of-hospital Cardiac Arrest
Key facts
- Who runs it
- Centre Hospitalier le Mans
- Where
- France31 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 1,380 people, planned
- Started
- 28 Sept 2024
- Expected to end
- 28 Mar 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Maintain MAP ≥ 90 mmHg
- Maintain MAP ≥ 65 mmHg
- Record updated
- 9 September 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Admission to ICU following an out-of-hospital cardiac arrest with an initially shockable or non-shockable rhythm
- Sustained ROSC defined as 20 minutes with signs of circulation without the need for chest compressions
- Under invasive mechanical ventilation for coma, defined as a Glasgow score ≤ 8/15
- Consent from a relative or of a procedure for emergency inclusion
Who cannot take part
- Extracorporeal circulatory support prior to inclusion
- In-hospital cardiac arrest (first cardiac arrest)
- Cardiac arrest in a context of multiple trauma
- Cardiac arrest in a context of hemorrhagic shock or severe hemorrhage necessitating hemostasis (surgery or radiological or endoscopic hemostasis)
- Cardiac arrest secondary to an acute brain disease (ischemic or hemorrhagic stroke, subarachnoid hemorrhage, severe traumatic brain injury)
- Known allergy to norepinephrine or to any of its excipients
- Modified Rankin score of 4 or 5 before cardiac arrest
- Age < 18 years
- Unwitnessed CA with initial rhythm of asystole
- Delay between ROSC and attempting randomisation > 6 hours
- Refractory shock :; Defined as a MAP < 65 mmHg for more than one hour on norepinephrine or epinephrine at a dose > 1 µg/kg/min despite adequate fluid resuscitation
- Decision to limit care before inclusion
- Inclusion in another interventional study in which the principal endpoint is neurological prognosis
- Pregnancy or breast feeding
- Adult patient deprived of freedom or under legal protection (patients under guardianship or curatorship) (article L1121-6 of the French Health Code)
- Non-French speaking
- Patient already included in this trial
- Absence of social security cover
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Out-of-hospital cardiac arrest is a public health problem for which overall survival is below 10%. Post-cardiac arrest syndrome is the principal cause of death in intensive care units (ICU), due to refractory shock or brain injuries secondary to anoxia. Brain anoxia is responsible for severe neurological sequelae that may be aggravated by cerebral hypoperfusion during the first few hours after the return of spontaneous circulation. Current recommendations are to ensure that arterial blood pressure is sufficient for the perfusion of organs, but no minimum threshold mean arterial pressure (MAP) has been defined. In practice, most teams target a MAP of at least 65 mmHg. Several observational studies have shown a correlation between MAP and neurological prognosis, patients with a higher initial MAP having a better outcome. Recent pilot studies have demonstrated the feasibility of increasing the target MAP after cardiac arrest, but conflicting results have been obtained concerning patient prognosis. These findings may be explained by changes to the autoregulation of the brain after cardiac arrest, with a shift of the curve towards the right, or its abolition. Cerebral blood flow is dependent on MAP, and a target MAP of 65 mmHg for these patients may result in insufficient brain perfusion. Conversely, a too high MAP might cause brain lesions due to vasogenic edema, hemorrhagic complications or excess perfusion in conditions of diminished brain metabolism. An interventional study is required to evaluate the effect of increasing MAP on neurofunctional outcome after cardiac arrest. Given the data available for brain autoregulation, the correlation between MAP and prognosis, and the risks theoretically associated with a higher MAP, investigator plans to compare a standard threshold of MAP (≥ 65 mmHg) with a high threshold of MAP (≥ 90 mmHg). Investigator hypothesizes that a high MAP within the first 24 hours after cardiac arrest will improve neurofunctional outcome.
The 2 groups in the trial
- high MAP thresholdTreatment being tested
Norepinephrine will be titrated to maintain MAP ≥ 90 mmHg. This threshold will be maintained for the 24 hours following inclusion by the perfusion of norepinephrine at an appropriate dose. From 24 hours after inclusion until ICU discharge, a MAP ≥ 65 mmHg will be targeted
Treatment: Maintain MAP ≥ 90 mmHg
- standard MAP thresholdExisting treatment, for comparison
Norepinephrine will be titrated to maintain MAP ≥ 65 mmHg. This target MAP will be maintained for 24 hours after randomization through the perfusion of norepinephrine at an appropriate flow rate. From 24 hours after inclusion until ICU discharge, a MAP ≥ 65 mmHg will be targeted
Treatment: Maintain MAP ≥ 65 mmHg
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Mean Arterial Pressure After Out-of-hospital Cardiac Arrest: the METAPHORE Randomized Trial
- Publications
- Record updated
- 9 September 2026